However , post-hoc analysis of the subgroup of patients not using chronic inhaled tobramycin showed a @ % difference ( @ % CI @-@ @ ) in relative change from baseline in percent-predicted FEV@ between the ataluren and placebo groups at week @ ( -@ % -LSB- -@ to @ -RSB- vs -@ % -LSB- -@ to -@ -RSB- ; nominal p = @ ) , and fewer pulmonary exacerbations in the ataluern group ( @ events -LSB- @-@ @ -RSB- vs @ events -LSB- @-@ @ -RSB- ; rate ratio @ -LSB- @-@ @ -RSB- ; nominal p = @ ) .